Wird geladen...
Alterations in genes other than EGFR/ALK/ROS1 in non-small cell lung cancer: trials and treatment options
During the last decade, we have seen tremendous progress in the therapy of lung cancer. Discovery of actionable mutations in EGFR and translocations in ALK and ROS1 have identified subsets of patients with excellent tumor response to oral targeted agents with manageable side effects. In this review,...
Gespeichert in:
| Veröffentlicht in: | Cancer Biol Med |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
Chinese Anti-Cancer Association
2016
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4850130/ https://ncbi.nlm.nih.gov/pubmed/27144064 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.28092/j.issn.2095-3941.2016.0008 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|